IMMPF NEWS
proactiveinvestors.co.uk
2d ago
ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round
ImmuPharma PLC (AIM:IMM, FRA:25I), the specialist drug discovery and development company, says it is actively progressing partnering discussions for its lead autoimmune technology platform, P140, as its primary strategic focus for 2026. The update came in a chairman's letter to shareholders following approval of two fundraising resolutions at a general meeting.
proactiveinvestors.co.uk
Mar 27
ImmuPharma shares surge 20% as P140 partnering talks advance
ImmuPharma PLC (AIM:IMM, FRA:25I) shares jumped 20% to 5.48p after the AIM-listed specialist drug discovery and development company said it is progressing discussions with a number of potential partners for its P140 autoimmune technology platform, including under signed confidentiality agreements, as it targets a value-enhancing licensing deal in 2026. The company's management team attended the Bio-Europe Spring healthcare conference in Lisbon this week, where a number of meetings were held in relation to P140, which ImmuPharma describes as a core value driver for the business.
proactiveinvestors.co.uk
Mar 27
ImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programme
ImmuPharma PLC (AIM:IMM, FRA:25I), the AIM-listed specialist drug discovery and development company, is progressing discussions with a number of potential partners for its P140 autoimmune technology platform, including under signed confidentiality agreements, as it targets a value-enhancing licensing deal in 2026. The company's management team attended the Bio-Europe Spring healthcare conference in Lisbon this week, where a number of meetings were held in relation to P140, which ImmuPharma describes as a core value driver for the business.
proactiveinvestors.co.uk
Mar 17
ImmuPharma raises up to £7.5m to accelerate diabetes drug development
AIM-listed drug developer targets Type 1 diabetes treatment while pursuing licensing deal for its lead autoimmune programme ImmuPharma PLC (AIM:IMM, FRA:25I) has launched a fundraise of up to £7.5 million to accelerate development of a new treatment for Type 1 diabetes, while reaffirming its confidence in completing a licensing deal for its lead drug programme this year. The company is raising £6 million through a subscription with Lanstead Capital Investors, a long-standing shareholder, which the firm described as Lanstead's largest single investment in ImmuPharma over the past decade.